euro adhoc: Intercell AG
Restructuring & Recapitalisations
Intercell
management board resolves EUR 150 million capital increase - HSR waiting period
for the strategic partnership with Novartis has expired
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
30.08.2007
Vienna (Austria), August 30, 2007 - The management board of Intercell AG today resolved, subject to the approval of the supervisory board, to issue 4.8 million new shares of common stock to its strategic partner Novartis at an issue price of EUR 31.25 per share. The subscription rights of existing shareholders will be excluded. The report on the exclusion of the statutory subscription rights will be published tomorrow in the Wiener Zeitung and on www.intercell.com.
Within the scope of a strategic alliance agreement concluded in early July 2007, Novartis has committed to subscribe for the newly issued shares, resulting in an investment of EUR 150 million into Intercell. One of the conditions to closing the strategic partnership was clearance under U.S. antitrust law. Today's resolution to make the capital increase effective follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (the "HSR Act"), whereby the strategic partnership can proceed under U.S. antitrust law. The waiting period expired in the ordinary course under the HSR Act 30 days after the initial filing. Completion of the capital increase and start of trading of the new shares on the Vienna Stock Exchange is expected for mid/end September 2007.
This document is not for release, publication or distribution in the United States of America.
This release does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States of America, Austria, Germany or any other jurisdiction. The securities of Intercell AG may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. It is not intended to register any securities of Intercell AG in the United States or to conduct a public offering in the United States, Austria, Germany or any other jurisdiction.
end of announcement euro adhoc 30.08.2007 16:27:51
Further inquiry note:
Intercell AG
Mag. Dott. Astrid Meinl
Corporate Communications
Tel. +43 1 20620-313
ameinl@intercell.com
Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market